PDCD1 and cancer: This was followed by significant advances with the development of anti-programmed cell death 1 (anti-PD-1) or its ligand (anti-PD-L1) mAb, such as nivolumab or pembrolizumab, becoming part of the standard treatment for multiple cancer types (2–4).